Business Wire

Medisca Drives Worldwide Access to Thyroid through Distribution License with SUANFARMA

Share

On March 16, 2022, Medisca, a global supplier of pharmaceutical ingredients and equipment, entered into an exclusive agreement with SUANFARMA, a European-based manufacturer and distributor of pharmaceutical ingredients, for the global supply and distribution of Thyroid Powder, USP, by leveraging its exclusive partnership with pharmaceutical manufacturer, Sichuan Deebio Pharmaceutical Co., Ltd (Deebio).

“Partnering with Deebio in June 2021 was a huge milestone for the pharmaceutical compounding industry as it allowed us to secure and stabilize the supply of high quality Thyroid Powder for the US market,” said Panagiota Danopoulos, Senior Vice President of Global Strategy & Innovation at Medisca.

“After going to market, we immediately realized that the demand for Thyroid Powder extended outside of our usual distribution channels to compounding pharmacies,” continued Danopoulos. “And we had the capacity to upscale supply to make this critical ingredient accessible to various markets, channels, and patients across the globe. A need we will now meet through our partnership with SUANFARMA.”

Already an existing partner and supplier of ingredients to Medisca, striking this agreement with SUANFARMA involved reinforcing a well-established symbiotic relationship between two companies committed to world-class quality, service, and price.

“The quality standards set, transparency created, and commitment established between Medisca and Deebio, is what gave us the confidence in choosing Medisca as our primary supplier of Thyroid Powder, USP,” said Gustavo Adolfo Porras, Head of Sales, North America at SUANFARMA. “We look forward to continuing to expand our strong relationship with Medisca.”

For Medisca, the mission is simple – to drive forward worldwide access to qualified products by developing strategic partnerships aligned to the same standards of quality, consistency, and affordability that define Medisca.

Medisca remains the leading supplier of Thyroid Powder, USP to compounding pharmacies. Available for purchase online here.

SUANFARMA will now streamline distribution to Medisca’s supply of Thyroid Powder, USP to other channels and markets.

About MEDISCA®

MEDISCA is a global leader in healthcare with well-established footings in pharmaceutical compounding and advancements in scientific labs, cosmetics, other healthcare industries. For 30+ years, MEDISCA has been serving pharmacies and allied healthcare institutions with cutting-edge offerings and passionate commitment, developing a worldwide network dedicated to personalized medicine. Through genuine relationships, worry-free experiences, convenient processes, and strategic global partnerships, MEDISCA provides top-quality and innovative products, industry-leading services, and world-class support systems. For more information visit www.medisca.com and follow us on Twitter at @medisca.

About SUANFARMA

SUANFARMA founded in 1993, is a B2B life science partner specialized in the development, production, and commercialization of ingredients for the pharmaceutical, veterinary and nutraceutical industries. Our facilities comply with the highest existing regulations in the pharmaceutical industry. With the support of a consolidated and strong commercial network with 12 local offices placed strategically around the world, SUANFARMA provides its services to more than 3.000 active customers in over 70 countries. For more information, visit www.suanfarma.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Panagiota Danopoulos
SVP Global Strategy & Innovation at Medisca
www.medisca.com
1-800-665-6334

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rubix Receives $100 Million Investment from LDA Capital5.7.2022 23:36:00 EEST | Press release

Rubix Blockchain Pte Ltd (Rubix) announced today it has secured a $100 million investment from LDA Capital Ltd to grow global operations, support the transition to Web3, and expand its green blockchain community. “Rubix is a gamechanger for international transactions. It’s exactly the type of innovative disruptor we look to partner with,” said Warren P. Baker III, managing partner at LDA Capital. “What sets the Rubix blockchain apart is its environmentally friendly crypto framework and focus on leveraging the Web3 technology to address some of the biggest issues society faces today. This isn’t just a coin, it’s a true transformation in how online transactions are processed.” This investment will allow Rubix to optimize growth in the Web3 space, expanding education opportunities, policy development, and Web2 to Web3 transition – enabling partners to build various apps on the platform including those that address social and environmental issues. The funds will also be used to increase in

Laserfiche Named a Leader in Nucleus Research Content Services and Collaboration Value Matrix 20225.7.2022 19:22:00 EEST | Press release

Laserfiche — the leading SaaS provider of intelligent content management and business process automation — has been named a Leader in the Nucleus Research Technology Value Matrix for Content Services and Collaboration for its deep industry expertise, ease of use and process automation features. Out of the 15 vendors evaluated, Laserfiche ranked highest for both functionality and usability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220705005673/en/ MPI CIO Joel Manfredo (left) shares upcoming plans to deploy Laserfiche as an enterprise solution with Laserfiche CIO Thomas Phelps. (Photo: Business Wire) “Over the past three years, digitization has become a core component of business survival across organizational sizes and industry types,” the report states. “Now, the ongoing prevalence of fully remote and hybrid work structures has highlighted the importance of having modern solutions for content management and collaborat

Clever Cloud Selects French Kalray for Its High-performance Storage Solutions to Optimize Its New Data Center5.7.2022 19:00:00 EEST | Press release

Clever Cloud, a European provider of automation and optimization solutions for websites and applications hosting, and Kalray (Paris:ALKAL) (Euronext Growth Paris: ALKAL), a leading provider of a new generation of processors and acceleration cards specialized in Intelligent Data Processing from Cloud to Edge, announce a partnership aimed at strengthening the relationship between the two companies for the deployment of next-generation storage solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220705005197/en/ Clever Cloud Clever Cloud, which is currently setting up in a third Parisian data center and strengthening its technical platform, has chosen to partner with French company Kalray and its Flashbox™, a new generation of NVMe storage array that can accommodate up to 24 PCI Express (NVMe) SSDs, for its high-performance storage solution. PERFORMANCE, RESILIENCE AND OPENNESS Without a host CPU (Central Processing Unit),

AM-Pharma Announces Publication of In Vivo Acute Kidney Injury Study Demonstrating Ilofotase Alfa’s Dual Protective Mechanism5.7.2022 18:00:00 EEST | Press release

AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced new data indicating that ilofotase alfa protects against ischemia-reperfusion induced acute kidney injury (AKI) has been published in the journal, Frontiers in Medicine-Nephrology. The study shows that ilofotase alfa protects the kidney through the activation of adenosine receptors in both rats and mice following ischemia reperfusion induced AKI. The publication is available now online at https://www.frontiersin.org/articles/10.3389/fmed.2022.931293/abstract. This study provides further insight into the mechanism of action of ilofotase alfa, showing that adenosine receptor signaling plays a role in the activity of the drug by restoring homeostasis through conversion of extracellular ATP into adenosine activating anti-inflammatory adenosine receptor signaling in common AKI animal models. The 1000 U/Kg dose tested in this study is, comparable to the dose currently being te

Innovaderm is Pleased to Announce the Acquisition of Excelsus Statistics5.7.2022 16:30:00 EEST | Press release

Innovaderm, a leading CRO in dermatology, has expanded its biometrics capacity following the acquisition of Excelsus Statistics, a Montreal-based company specialized in biostatistical and SAS programming services with a special expertise in adaptive trial design, as well as activities in many different therapeutic areas. “We are pleased to grow our Biometrics team with the addition of new talent,” says Dr. Robert Bissonnette, Innovaderm’s founder and CEO. “Innovaderm has a reputation for excellence in clinical research in dermatology, as well as attracting committed professionals in the field. Our collective expertise will allow us to offer biometrics services across different therapeutic areas and fulfill the growing needs of our clients.” Since 2014, Excelsus Statistics has served as a collaborator in many studies managed by Innovaderm. The integration of the two companies will allow Excelsus Statistics’ existing clients to now have access to full CRO services including data manageme

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom